CCA — Cato Certified Associate — Questions and Answers

Question 1: Which US government agency administers the Foreign Corrupt Practices Act (FCPA) as it relates to trade compliance?

The Bureau of Industry and Security (BIS)
The Department of Justice and the SEC (Correct answer)
The Office of Foreign Assets Control (OFAC)
CBP and ICE jointly

Correct answer: The Department of Justice and the SEC

The FCPA is jointly enforced by the Department of Justice (criminal violations) and the Securities and Exchange Commission (civil violations).

Question 2: What is 'database lock' in the context of clinical trial close-out?

Encrypting the electronic CRF to prevent hacking
The formal process of finalizing the clinical database after all data cleaning is complete, preventing further changes (Correct answer)
Closing the randomization system
Archiving all paper source documents

Correct answer: The formal process of finalizing the clinical database after all data cleaning is complete, preventing further changes

Database lock is the point at which all data cleaning is complete, the database is reviewed and approved, and it is formally locked against further changes prior to analysis.

Question 3: What is the purpose of a 'Data Safety Monitoring Board' (DSMB) in a clinical trial?

To train site staff on protocol procedures
To manage the randomization process
To audit financial data from the sponsor
To independently review accumulating safety and efficacy data and recommend continuation, modification, or stopping of the trial (Correct answer)

Correct answer: To independently review accumulating safety and efficacy data and recommend continuation, modification, or stopping of the trial

A DSMB (or IDMC) independently monitors accumulating trial data to protect subject safety and can recommend stopping or modifying the trial based on emerging safety signals.

Question 4: What is the consequence for a customs broker whose license is revoked by CBP under 19 CFR 111.53?

The broker is permanently barred from re-applying for a customs broker license
The broker's clients are automatically transferred to the nearest CBP-approved broker
The broker must immediately cease all customs business and may not apply for a new license for a period set by CBP (Correct answer)
The broker may continue operating under a temporary permit for up to one year

Correct answer: The broker must immediately cease all customs business and may not apply for a new license for a period set by CBP

Upon revocation under 19 CFR 111.53, a broker must immediately cease conducting customs business, and CBP may set conditions including a waiting period before re-application.

Question 5: Who is responsible for submitting IND annual safety reports to the FDA for a US clinical trial?

The IRB/IEC
The Sponsor (Correct answer)
The CRO project manager
The Principal Investigator

Correct answer: The Sponsor

The Sponsor holds the IND and is responsible for submitting the annual IND safety report to the FDA as required by 21 CFR 312.33.

Question 6: Under FDA regulations, an Investigational New Drug (IND) application must be submitted before:

Administering an investigational drug to humans in the US (Correct answer)
Conducting Phase II studies only
Shipping investigational product to trial sites
Publishing the study results

Correct answer: Administering an investigational drug to humans in the US

An IND application must be filed and allowed to go into effect before any investigational drug is administered to human subjects in the US.

Question 7: What activities must be completed BEFORE a site close-out visit can occur?

Site staff have been recruited for the next study
Only the investigator's signature on the final report
The clinical study report has been submitted to the FDA
All subject visits completed or early terminated, all data queries resolved, IP reconciled, and all SAEs resolved or with final status (Correct answer)

Correct answer: All subject visits completed or early terminated, all data queries resolved, IP reconciled, and all SAEs resolved or with final status

Before COV, all subject participation must be completed, data queries resolved, IP fully reconciled, and SAEs documented to their final status.

Question 8: Which risk is most directly mitigated by having a pre-specified Data Monitoring Committee (DMC) for an ongoing trial?

Risk of incorrect randomization assignments
Risk of continuing a trial that is showing unexpected harm or clear benefit (Correct answer)
Risk of missing data in the case report forms
Risk of protocol non-compliance at sites

Correct answer: Risk of continuing a trial that is showing unexpected harm or clear benefit

A DMC (also called DSMB) independently reviews interim safety and efficacy data to recommend stopping or modifying the trial if there is evidence of unexpected harm, clear benefit, or futility.

Question 9: Which system is commonly used for electronic data capture in clinical trials?

EDC system (Correct answer)
eTMF
CRM software
IRB Portal

Correct answer: EDC system

EDC (Electronic Data Capture) systems like Medidata and Oracle Clinical help streamline data entry and validation.

Question 10: What is a 'screen failure' in the context of clinical trial enrollment?

A potential subject who is assessed for eligibility but does not meet inclusion/exclusion criteria and cannot be enrolled (Correct answer)
A subject who drops out after randomization
A subject who fails to complete all study visits
A randomized subject who does not take the IP

Correct answer: A potential subject who is assessed for eligibility but does not meet inclusion/exclusion criteria and cannot be enrolled

A screen failure occurs when a potential subject undergoes eligibility screening but does not meet the criteria required for enrollment into the trial.

Question 11: Why must informed consent be obtained before trial participation?

To meet sponsor deadlines
To satisfy insurance providers
To ensure voluntary, informed participation (Correct answer)
To replace IRB approval

Correct answer: To ensure voluntary, informed participation

Informed consent ensures that participants voluntarily agree to join the study with full knowledge of risks and benefits.

Question 12: Which regulatory body must approve advertising materials used for subject recruitment in US-based clinical trials?

The sponsor's marketing department
The IRB/IEC prior to use (Correct answer)
The local hospital ethics committee only
The FDA Office of Clinical Pharmacology

Correct answer: The IRB/IEC prior to use

All recruitment advertising materials must be reviewed and approved by the IRB/IEC before use to ensure they are not coercive and are appropriate for the target population.

Question 13: Which ICH guideline provides the foundational framework for the design, conduct, recording, and reporting of clinical trials?

ICH E3
ICH E9
ICH E6(R2) (Correct answer)
ICH E2A

Correct answer: ICH E6(R2)

ICH E6(R2) is the Good Clinical Practice (GCP) guideline that establishes international standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials.

Question 14: What is the main role of a clinical data manager?

Manage IRB reviews
Recruit participants
Coordinate marketing strategies
Ensure data accuracy and integrity (Correct answer)

Correct answer: Ensure data accuracy and integrity

Clinical data managers are responsible for collecting, validating, and managing trial data to ensure accuracy and compliance.

Question 15: Under 19 USC 1484, who has the right to make entry of imported merchandise in the United States?

The importer of record or their authorized agent, including a licensed customs broker (Correct answer)
Only a licensed customs broker acting on behalf of the importer
The carrier who transported the goods to the US port of entry
Only the owner or purchaser of the goods named on the bill of lading

Correct answer: The importer of record or their authorized agent, including a licensed customs broker

19 USC 1484 grants the right to make entry to the importer of record or their duly authorized agent, which can include a licensed customs broker with a valid power of attorney.

Question 16: In the context of GCP, 'blinding' or 'masking' is used primarily to:

Anonymize participant data for publication
Protect the investigator's identity from the sponsor
Reduce bias by preventing knowledge of treatment assignment (Correct answer)
Conceal adverse events from regulatory agencies

Correct answer: Reduce bias by preventing knowledge of treatment assignment

Blinding prevents knowledge of treatment assignment from influencing participant behavior or investigator assessments, thereby reducing bias.

Question 17: What is a 'follow-up safety report' in clinical trial pharmacovigilance?

An updated report submitted when new information becomes available after the initial SAE report (Correct answer)
A report filed by the IRB 30 days after the SAE
A report submitted only when the subject recovers
A report generated at study lock

Correct answer: An updated report submitted when new information becomes available after the initial SAE report

A follow-up report is submitted when additional clinically relevant information about a previously reported SAE becomes available.

Question 18: What must occur before a clinical trial can begin?

IRB approval (Correct answer)
Site selection
Contract with CRO
Public announcement

Correct answer: IRB approval

Approval from an Institutional Review Board (IRB) is required to ensure ethical standards are met.

Question 19: How does CATO's 'User Activity' report help with insider threat detection?

It compares user activity against a global threat feed
It blocks users automatically when anomalies are detected
It encrypts user activity data to prevent data leakage
It provides detailed per-user traffic logs showing accessed destinations, volumes, and times (Correct answer)

Correct answer: It provides detailed per-user traffic logs showing accessed destinations, volumes, and times

CATO's User Activity report provides detailed per-user traffic logs that allow administrators to identify unusual access patterns, volumes, or destinations indicative of insider threats.

Question 20: The Belmont Report's principle of 'justice' in research ethics is most concerned with:

Legal accountability of researchers
Ensuring participants receive fair compensation
Fair distribution of research burdens and benefits across populations (Correct answer)
Protecting intellectual property from sponsors

Correct answer: Fair distribution of research burdens and benefits across populations

Justice requires that the selection of research subjects be equitable so that no group bears a disproportionate burden or is excluded from benefits.

Question 21: Which study design is considered the gold standard for evaluating the efficacy of a new treatment?

Open-label observational study
Retrospective cohort study
Randomized double-blind placebo-controlled trial (Correct answer)
Single-arm dose-escalation study

Correct answer: Randomized double-blind placebo-controlled trial

The randomized double-blind placebo-controlled trial minimizes bias through randomization, blinding, and a control comparator, making it the gold standard for establishing treatment efficacy.

Question 22: Under GCP, how long must IP accountability records typically be retained after the trial ends?

Per sponsor/regulatory requirements, typically at least 2–15 years depending on jurisdiction (Correct answer)
2 years
30 days
1 year

Correct answer: Per sponsor/regulatory requirements, typically at least 2–15 years depending on jurisdiction

IP accountability records must be retained per applicable regulatory requirements and sponsor instructions, commonly ranging from 2 to 15+ years.

Question 23: What is the function of CATO's 'Application Analytics' report in data management?

To identify which SaaS and web applications consume the most bandwidth and sessions (Correct answer)
To configure application-layer firewall rules
To encrypt application traffic automatically
To provision new applications in the CATO cloud

Correct answer: To identify which SaaS and web applications consume the most bandwidth and sessions

CATO's Application Analytics report identifies bandwidth consumption and session counts per application, enabling administrators to understand application usage trends.

Question 24: A clinical trial protocol includes an 'efficacy estimand.' What does this concept define?

The number of sites required to meet enrollment targets
The precise treatment effect to be estimated, accounting for intercurrent events (Correct answer)
The regulatory pathway for product approval
The statistical software to be used for analysis

Correct answer: The precise treatment effect to be estimated, accounting for intercurrent events

An estimand precisely defines the treatment effect of interest, including how intercurrent events (like treatment discontinuation) are handled, per ICH E9(R1).

Question 25: Which ICH guideline provides the framework for clinical safety data management and expedited reporting of adverse drug reactions?

ICH E2A (Correct answer)
ICH E8
ICH E10
ICH E6 (GCP)

Correct answer: ICH E2A

ICH E2A provides the definitions and standards for clinical safety data management, including criteria for expedited reporting of adverse drug reactions.

Question 26: What is the primary purpose of inclusion and exclusion criteria in a clinical trial protocol?

To reduce the cost of the study
To increase enrollment speed
To satisfy FDA formatting requirements
To define the target study population and ensure participant safety (Correct answer)

Correct answer: To define the target study population and ensure participant safety

Inclusion and exclusion criteria define who may participate, ensuring the study population matches the scientific objectives and that vulnerable or at-risk individuals are appropriately protected.

Question 27: A participant in a Phase II oncology trial loses decision-making capacity mid-study. GCP guidance recommends:

Continuing participation using previously collected consent
Obtaining consent from a legally authorized representative to continue (Correct answer)
Obtaining a waiver of consent from the IRB
Withdrawing the participant immediately regardless of benefit

Correct answer: Obtaining consent from a legally authorized representative to continue

GCP requires that if a participant loses capacity, a legally authorized representative must provide consent for continued participation.

Question 28: Why is subject retention important in longitudinal clinical trials?

It reduces the cost of IP supply
It prevents missing data, maintains statistical power, and reduces bias that could affect trial validity (Correct answer)
It allows the study to close earlier
It eliminates the need for screen failure documentation

Correct answer: It prevents missing data, maintains statistical power, and reduces bias that could affect trial validity

High subject retention is critical to maintaining statistical power, minimizing missing data, and preventing attrition bias that could invalidate trial results.

Question 29: Which section of a clinical trial protocol defines the scientific rationale and purpose of the study?

Eligibility Criteria
Background and Introduction (Correct answer)
Statistical Analysis Plan
Administrative Information

Correct answer: Background and Introduction

The Background and Introduction section provides the scientific rationale, prior research, and purpose that justify conducting the study.

Question 30: What is an adaptive clinical trial design?

A design that does not require randomization
A design that uses historical controls instead of a placebo group
A design used exclusively in Phase I studies
A design that allows pre-specified modifications to the trial based on interim data (Correct answer)

Correct answer: A design that allows pre-specified modifications to the trial based on interim data

Adaptive designs permit pre-specified, data-driven modifications to study parameters (such as sample size or dose) during the trial while maintaining scientific validity and controlling the type I error rate.

Question 31: What is the purpose of a feasibility assessment conducted before finalizing a clinical trial protocol?

To establish the statistical analysis plan
To verify that the protocol meets FDA formatting standards
To evaluate whether sites can enroll eligible participants and conduct the trial as designed (Correct answer)
To approve the informed consent document

Correct answer: To evaluate whether sites can enroll eligible participants and conduct the trial as designed

Feasibility assessments determine whether investigative sites have adequate patient populations, infrastructure, and staff capabilities to successfully execute the protocol as written.

Question 32: What is the purpose of a drug reconciliation at the end of a clinical trial?

To determine the study's statistical power
To finalize site payment invoices
To prepare the clinical study report
To verify that all dispensed, returned, and destroyed IP quantities balance with what was received (Correct answer)

Correct answer: To verify that all dispensed, returned, and destroyed IP quantities balance with what was received

Drug reconciliation confirms that all IP received is accounted for through dispensing records, subject returns, and destruction documentation.

Question 33: What is an 'emergency unblinding' procedure in the context of IP management?

Transfer of IP to another site
A process allowing rapid disclosure of a subject's treatment assignment when medically necessary (Correct answer)
Destruction of IP at close-out
Routine disclosure of treatment assignments at study end

Correct answer: A process allowing rapid disclosure of a subject's treatment assignment when medically necessary

Emergency unblinding allows rapid determination of a subject's treatment assignment when knowledge is essential for the subject's medical management.

Question 34: Which CATO report would an administrator use to identify which users are consuming excessive network bandwidth?

Top Users by Traffic (Correct answer)
Site Health Dashboard
PoP Latency Report
Threats Overview

Correct answer: Top Users by Traffic

The Top Users by Traffic report ranks users by their bandwidth consumption, making it the appropriate tool for identifying excessive network usage.

Question 35: If a site has not enrolled any subjects within 6 months of initiation, what action should the monitor consider recommending?

Re-train all site staff
Increase investigational product supply
Consider site non-performance review or closure (Correct answer)
Request a protocol amendment

Correct answer: Consider site non-performance review or closure

A site that fails to enroll patients within a reasonable period after initiation may be considered for a non-performance review or deactivation.

Question 36: When a CATO administrator exports a report to CSV, which use case is this format most appropriate for?

Further analysis in spreadsheet tools or import into external data systems (Correct answer)
Real-time monitoring dashboards requiring live data updates
Automated API integration with third-party security tools
Archiving logs for long-term cold storage compliance

Correct answer: Further analysis in spreadsheet tools or import into external data systems

CSV export is most appropriate for further analysis in spreadsheet tools like Excel or for importing into external data systems that accept tabular data.

Question 37: What should a CRA do if drug accountability records do not reconcile during a monitoring visit?

Correct the records themselves to make them balance
Unblind the subject's treatment to resolve the issue
Ignore minor discrepancies under 5 units
Document the discrepancy, investigate the cause with site staff, and report findings to the sponsor (Correct answer)

Correct answer: Document the discrepancy, investigate the cause with site staff, and report findings to the sponsor

Unresolved drug accountability discrepancies must be documented, investigated with site staff, and escalated to the sponsor for review.

Question 38: What action must the investigator take upon learning of a fatal SAE occurring in a study subject?

File the event in the source documents and take no further immediate action
Only notify the IRB if it was related to the IP
Wait until the next monitoring visit to report it
Report it to the sponsor immediately and to the IRB/IEC within required timeframes (Correct answer)

Correct answer: Report it to the sponsor immediately and to the IRB/IEC within required timeframes

Fatal SAEs must be reported to the sponsor immediately (often within 24 hours) and to the IRB/IEC within required timeframes per protocol and regulations.

Question 39: What is the significance of the 'lot number' on investigational product labels?

It is the subject's kit number
It enables traceability of the product batch for quality and recall purposes (Correct answer)
It indicates the subject's randomization assignment
It confirms IRB approval of the product

Correct answer: It enables traceability of the product batch for quality and recall purposes

The lot number on IP labeling allows the manufacturer to trace the specific production batch, supporting quality control and recall management if needed.

Question 40: What is the term for investigational product that has been returned unused by subjects or retrieved after trial completion?

Destroyed product
Expired stock
Returned IP (Correct answer)
Back-up supply

Correct answer: Returned IP

Unused IP returned by subjects or retrieved at close-out is termed 'returned IP' and must be documented and managed per sponsor instructions.

Question 41: What is the purpose of a 'site decommissioning checklist' at the end of a clinical trial?

To list all subjects who did not complete the trial
To calculate final site payments
To ensure all close-out tasks—IP return, document archiving, equipment return, and staff notifications—are completed systematically (Correct answer)
To audit the IP manufacturer

Correct answer: To ensure all close-out tasks—IP return, document archiving, equipment return, and staff notifications—are completed systematically

A site decommissioning checklist provides a systematic guide to ensure every close-out requirement is fulfilled before the site is formally closed.

Question 42: A protocol deviation that significantly affects the rights, safety, or well-being of participants is classified as a:

Minor deviation
Regulatory filing
Serious breach (Correct answer)
Protocol amendment

Correct answer: Serious breach

A serious breach is a deviation that significantly impacts participant safety, rights, or data integrity and requires regulatory notification.

Question 43: Why must investigational product never be dispensed to a subject before randomization?

Because pre-randomization dispensing violates the protocol and could compromise blinding and data integrity (Correct answer)
Because the CRF has not been opened yet
To comply with IRB timelines
To avoid wasting supply

Correct answer: Because pre-randomization dispensing violates the protocol and could compromise blinding and data integrity

Dispensing IP before randomization is a protocol deviation that compromises trial integrity and subject allocation to treatment arms.

Question 44: What is an essential document for participant protection in a clinical trial?

Budget agreement
Site monitoring log
Informed consent form (Correct answer)
Protocol deviation memo

Correct answer: Informed consent form

The informed consent form ensures participants understand the risks and procedures before joining the trial.

Question 45: A sponsor's written procedures for monitoring clinical trials are formally documented in which type of document?

The protocol synopsis
Standard Operating Procedures (SOPs) (Correct answer)
The Investigator Brochure
The Clinical Study Report

Correct answer: Standard Operating Procedures (SOPs)

SOPs provide written instructions for carrying out sponsor monitoring and other trial functions in a consistent, compliant manner.

Question 46: The Declaration of Helsinki's requirement for a 'post-study provision' means that:

Participants should have access to beneficial interventions identified in the study (Correct answer)
Data must be archived for future research
Participants must be compensated financially after the trial
Sponsors must publish all negative results

Correct answer: Participants should have access to beneficial interventions identified in the study

The Declaration of Helsinki states that participants who benefited from study interventions should have access to them after the study ends.

Question 47: Which element is essential for ensuring the protocol clearly defines what constitutes the primary endpoint?

Operational definition including measurement method, timing, and assessor (Correct answer)
IRB contact information
List of excluded medications
Site feasibility criteria

Correct answer: Operational definition including measurement method, timing, and assessor

A primary endpoint must be precisely operationalized with a clear measurement method, the time point of assessment, and who performs the assessment to ensure consistent data collection.

Question 48: Who at an investigative site is responsible for assessing causality of adverse events to the investigational product?

The Principal Investigator or qualified sub-investigator (Correct answer)
The Clinical Research Associate (CRA)
The IRB/IEC
The sponsor's medical monitor

Correct answer: The Principal Investigator or qualified sub-investigator

The Principal Investigator or a qualified sub-investigator is responsible for assessing the causal relationship between the IP and the observed adverse event.

Question 49: Under 21 CFR Part 50, a 'short form' written consent document may be used when:

The study involves minimal risk only
Electronic consent is unavailable
The IRB determines that oral presentation of consent elements is appropriate and a witness is present (Correct answer)
The participant is a minor

Correct answer: The IRB determines that oral presentation of consent elements is appropriate and a witness is present

A short form may be used when the IRB approves oral presentation of consent elements to the participant, with a witness signing the document.

Question 50: During a site initiation visit (SIV), what is the primary purpose of reviewing the delegation log?

To check subject enrollment numbers
To reconcile investigational product inventory
To verify sponsor payments
To confirm staff qualifications and assigned responsibilities (Correct answer)

Correct answer: To confirm staff qualifications and assigned responsibilities

The delegation log is reviewed at SIV to confirm that all site staff are properly qualified and have been assigned appropriate trial responsibilities.

Question 51: What does the Declaration of Helsinki provide?

Participant recruitment ads
Marketing strategies
Ethical principles for medical research (Correct answer)
Budget planning guidance

Correct answer: Ethical principles for medical research

This document outlines ethical principles for medical research involving human subjects, developed by the World Medical Association.

Question 52: Which term refers to the complete set of standard operating procedures, instructions, and specifications for conducting a clinical trial?

Protocol
Master File
Investigator Brochure
Quality Management System (Correct answer)

Correct answer: Quality Management System

A Quality Management System (QMS) encompasses the SOPs, processes, and quality standards that govern trial conduct.

Question 53: What is the purpose of the 'end of trial notification' submitted to regulatory authorities?

To notify the IRB that subject visits are complete
To request IND cancellation for all future trials
To officially inform regulatory authorities that the clinical trial has ended in compliance with regulatory requirements (Correct answer)
To submit the final clinical study report

Correct answer: To officially inform regulatory authorities that the clinical trial has ended in compliance with regulatory requirements

An end of trial notification formally informs regulatory authorities that the trial has concluded, triggering applicable post-trial reporting and archiving obligations.

Question 54: Which document describes the preclinical and clinical data on an investigational product to guide safe use in a clinical trial?

Case Report Form
Protocol Synopsis
Master File Index
Investigator Brochure (Correct answer)

Correct answer: Investigator Brochure

The Investigator Brochure (IB) compiles all available clinical and non-clinical data on the investigational product to guide investigators in conducting the trial safely.

Question 55: An investigator receives a protocol deviation report from a monitor. Under GCP, the investigator must:

Document the deviation, assess impact, and implement corrective actions (Correct answer)
Immediately suspend the study pending IRB review
Send the deviation directly to the FDA without sponsor notification
File the report and take no further action if minor

Correct answer: Document the deviation, assess impact, and implement corrective actions

GCP requires investigators to document all deviations, evaluate their impact on participant safety and data integrity, and implement CAPA as needed.

Question 56: A Phase II clinical trial is primarily designed to:

Confirm efficacy in large diverse populations
Assess preliminary efficacy and dosing in patients with the target disease (Correct answer)
Establish safety in healthy volunteers
Conduct post-marketing surveillance

Correct answer: Assess preliminary efficacy and dosing in patients with the target disease

Phase II trials focus on evaluating preliminary efficacy, determining optimal dosing, and further characterizing safety in patients who have the disease being studied.

Question 57: What is a 'communication log' maintained for in site management?

Listing IRB meeting outcomes
Tracking adverse events by severity
Recording IP dispensing and returns
Documenting all significant communications between the site and sponsor/CRO (Correct answer)

Correct answer: Documenting all significant communications between the site and sponsor/CRO

A communication log records all important exchanges between the site and sponsor/CRO to ensure accountability and an audit trail.

Question 58: An importer claims duty-free treatment under the Generalized System of Preferences (GSP) for goods from an eligible beneficiary country. What is the primary documentary requirement to support this claim?

A ruling letter from CBP confirming GSP eligibility for that specific product
A GSP Form A Certificate of Origin issued by the exporting country's customs authority
A statement on the commercial invoice attesting to GSP eligibility, or Form A if required by the specific country (Correct answer)
No documentation is required; the importer simply annotates the entry summary

Correct answer: A statement on the commercial invoice attesting to GSP eligibility, or Form A if required by the specific country

GSP claims are typically supported by a declaration on the commercial invoice or, for certain beneficiary countries, a Form A Certificate of Origin issued by the foreign government.

Question 59: Which of the following actions constitutes 'gross negligence' under CBP's penalty statute (19 USC 1592)?

An act or omission done with actual knowledge of or wanton disregard for relevant facts and a reckless disregard for legal obligations (Correct answer)
Failure to file entry documents within the 15-day free time period
An isolated clerical error on a commercial invoice
Using an incorrect country of origin on a label due to a supplier error

Correct answer: An act or omission done with actual knowledge of or wanton disregard for relevant facts and a reckless disregard for legal obligations

Under 19 USC 1592, gross negligence is defined as an act or omission that results from an indifference to or reckless disregard for relevant facts and a reckless disregard for legal obligations.

Question 60: What is the primary ethical principle that guides subject recruitment in clinical trials?

Voluntary participation based on freely given informed consent without coercion (Correct answer)
Prioritizing subjects with the best insurance coverage
Speed of enrollment
Maximizing the number of subjects to increase statistical power

Correct answer: Voluntary participation based on freely given informed consent without coercion

Voluntary participation based on informed consent without undue influence or coercion is the foundational ethical principle of subject recruitment.

Question 61: What is the difference between 'causality assessment' and 'expectedness' in adverse event reporting?

They are the same concept
Causality is only assessed by the IRB; expectedness is assessed by the subject
Expectedness refers to how common the event is in the general population
Causality assesses the relationship of the event to the investigational product; expectedness compares the event to what is described in the reference safety document (Correct answer)

Correct answer: Causality assesses the relationship of the event to the investigational product; expectedness compares the event to what is described in the reference safety document

Causality determines if the adverse event is related to the IP, while expectedness compares the event to descriptions in the Investigator Brochure or labeling.

Question 62: What is a 'sentinel event' in clinical trial safety monitoring?

An adverse event that does not require reporting
The first randomized subject in a trial
A scheduled interim analysis
A serious and typically unexpected adverse event that signals a potential safety concern requiring immediate investigation (Correct answer)

Correct answer: A serious and typically unexpected adverse event that signals a potential safety concern requiring immediate investigation

A sentinel event is a serious, usually unexpected adverse outcome that serves as a signal requiring prompt investigation to prevent recurrence or further harm.

Question 63: Which historical event most directly led to the development of the Nuremberg Code?

The Willowbrook hepatitis studies
The Tuskegee Syphilis Study
The Thalidomide tragedy
Nazi medical experiments during World War II (Correct answer)

Correct answer: Nazi medical experiments during World War II

The Nuremberg Code (1947) was drafted in response to Nazi physicians' unethical medical experiments on prisoners during World War II.

Question 64: What is a 'recruitment plan' in clinical trial operations?

A plan for recruiting new staff to the site
A schedule for monitoring visits based on enrollment
A financial plan for subject reimbursements
A strategy outlining how and when target enrollment numbers will be achieved, including outreach methods and timelines (Correct answer)

Correct answer: A strategy outlining how and when target enrollment numbers will be achieved, including outreach methods and timelines

A recruitment plan details the strategies, timelines, and resources the site will use to meet its enrollment targets during the trial.

Question 65: Under GCP, source documents are best defined as:

The final study database after data cleaning
Original records and certified copies from which CRF data are transcribed (Correct answer)
IRB approval letters
The sponsor's protocol and amendments

Correct answer: Original records and certified copies from which CRF data are transcribed

Source documents are the original records (e.g., hospital charts, lab reports) that provide the first-captured data for clinical trial entries.

Question 66: In a double-blind randomized trial, who at the site is permitted to know the treatment assignment for a subject before unblinding?

Any member of the study team
The CRA during monitoring visits
The unblinded pharmacist or designee managing IP dispensing (Correct answer)
The principal investigator at all times

Correct answer: The unblinded pharmacist or designee managing IP dispensing

In a double-blind design, only the unblinded pharmacist or designated unblinded staff managing IP may know treatment assignment; all other site staff remain blinded.

Question 67: What does 'intent-to-treat' (ITT) analysis mean in a clinical trial?

Analyzing subjects who received at least one dose of active treatment
Analyzing only subjects who completed all protocol-required visits
Analyzing all randomized subjects regardless of protocol adherence or treatment received (Correct answer)
Excluding subjects with protocol deviations from the primary analysis

Correct answer: Analyzing all randomized subjects regardless of protocol adherence or treatment received

ITT analysis includes all randomized participants in the group to which they were assigned, preserving the benefits of randomization.

Question 68: In CATO's reporting, what is the significance of 'Blocked' vs 'Monitored' action types in IPS events?

Blocked events require manual review; Monitored events are auto-resolved
Blocked events triggered alerts; Monitored events were silently dropped
Blocked events were quarantined; Monitored events were encrypted
Blocked events had traffic stopped; Monitored events were logged but allowed through (Correct answer)

Correct answer: Blocked events had traffic stopped; Monitored events were logged but allowed through

In CATO IPS events, Blocked means traffic was actively stopped, while Monitored means the threat was detected and logged but the traffic was permitted to pass.

Question 69: What document accompanies each shipment of investigational product (IP) to a clinical site?

Delegation log
IRB approval letter
Protocol synopsis
Drug shipment manifest / packing slip (Correct answer)

Correct answer: Drug shipment manifest / packing slip

A drug shipment manifest or packing slip accompanies each IP shipment to verify contents, quantities, and storage conditions.

Question 70: During site management, what is the recommended frequency for a high-enrolling site in a Phase III trial?

Once per enrollment cycle
Annual monitoring visits only
Monitoring only at study close-out
More frequent monitoring visits (e.g., monthly) based on risk (Correct answer)

Correct answer: More frequent monitoring visits (e.g., monthly) based on risk

Risk-based monitoring principles call for more frequent visits at high-enrolling sites to ensure data quality and subject safety.

Question 71: How does CATO's 'Aggregate Events' feature help manage high-volume security event data?

It groups similar repetitive events into a single summary record to reduce noise (Correct answer)
It distributes events across multiple database shards for performance
It compresses raw event files to reduce storage costs
It prioritizes critical events over informational events in the queue

Correct answer: It groups similar repetitive events into a single summary record to reduce noise

CATO's Aggregate Events feature consolidates similar repetitive events (such as the same blocked connection firing repeatedly) into a single summarized record, reducing alert fatigue.

Question 72: A sponsor discovers a serious unexpected adverse drug reaction mid-trial. Under GCP, the expedited reporting window to regulatory authorities is typically:

30 calendar days
24 hours
15 calendar days for all SUSARs
7 calendar days for fatal/life-threatening events (Correct answer)

Correct answer: 7 calendar days for fatal/life-threatening events

Fatal or life-threatening SUSARs must be reported to regulators within 7 calendar days; other SUSARs within 15 calendar days.

Question 73: A research site experiences a fire that destroys original paper case report forms. GCP requires the investigator to:

Immediately close the site
Reconstruct the CRFs from memory
Notify the sponsor, document the event, and implement data recovery from certified copies or source documents (Correct answer)
Withdraw all affected participants from analysis

Correct answer: Notify the sponsor, document the event, and implement data recovery from certified copies or source documents

Lost essential documents must be reported to the sponsor; recovery from certified copies or remaining source documents should be attempted, and the incident fully documented.

Question 74: Which role is responsible for monitoring site compliance and data integrity?

Clinical Research Associate (CRA) (Correct answer)
Regulatory Affairs Manager
Principal Investigator
Data Entry Clerk

Correct answer: Clinical Research Associate (CRA)

Clinical Research Associates (CRAs) ensure that clinical sites follow protocols and accurately report trial data.

Question 75: What strategy is commonly used to improve subject retention in long-term clinical trials?

Increasing financial incentives mid-trial without IRB approval
Reducing the frequency of required visits regardless of protocol
Regular check-in calls, visit reminders, simplified visit scheduling, and reimbursing travel costs (Correct answer)
Allowing proxy consent for adults who miss visits

Correct answer: Regular check-in calls, visit reminders, simplified visit scheduling, and reimbursing travel costs

Proactive contact, reminder systems, flexible scheduling, and reimbursing inconvenience costs are evidence-based strategies for improving retention.

Question 76: What is the 'washout period' in a clinical trial protocol?

The time between screening and randomization
The duration of the study follow-up
The time required to train site staff
A period between treatment phases during which a prior treatment is cleared from the body (Correct answer)

Correct answer: A period between treatment phases during which a prior treatment is cleared from the body

A washout period in crossover or sequential studies allows previously administered treatments to be eliminated from the body before the next treatment is started, preventing carryover effects.

Question 77: How long must clinical trial records typically be retained at the investigative site under FDA regulations?

1 year after trial completion
5 years from the last subject's last visit
Indefinitely
2 years after the latest marketing application is approved, or 2 years after the IND is withdrawn (per 21 CFR 312.62) (Correct answer)

Correct answer: 2 years after the latest marketing application is approved, or 2 years after the IND is withdrawn (per 21 CFR 312.62)

Under 21 CFR 312.62, investigators must retain records for 2 years following the date a marketing application is approved, or 2 years after the IND is discontinued.

Question 78: Under GCP, the minimum age for an individual to provide independent informed consent without a guardian in the US is governed by:

FDA regulation, fixed at 17 years
The IRB, which sets it case-by-case
ICH E6(R2) globally set at 16 years
State law, which typically sets the age of majority at 18 (Correct answer)

Correct answer: State law, which typically sets the age of majority at 18

In the US, the age for independent consent is determined by state law (generally 18), and federal regulations defer to applicable state law for the age of majority.

Question 79: A sponsor is conducting a decentralized clinical trial (DCT) with remote visits. GCP requires that source data captured remotely must be:

Printed and signed by the investigator within 24 hours
Stored exclusively at the sponsor's data center
Verified only at the end of the trial
Attributable, legible, contemporaneous, original, and accurate (ALCOA) (Correct answer)

Correct answer: Attributable, legible, contemporaneous, original, and accurate (ALCOA)

Regardless of the trial modality, all source data must meet ALCOA principles to ensure data integrity and traceability.

Question 80: When a clinical monitor identifies a pattern of missing data across multiple subjects at a site, what is the most appropriate first action?

Document the finding and discuss with the site to identify the root cause (Correct answer)
Immediately notify the FDA
Terminate the site from the trial
Amend the protocol to remove the missing data field

Correct answer: Document the finding and discuss with the site to identify the root cause

The monitor should document the finding, communicate with site staff, and work to identify and remediate the root cause of missing data.

Question 81: Which of the following is a core ethical principle in clinical research?

Reducing protocol length
Respect for persons (Correct answer)
Speeding up trials
Minimizing paperwork

Correct answer: Respect for persons

Respect for persons includes informed consent, acknowledging autonomy, and protecting those with diminished autonomy.

Question 82: When must an Importer Security Filing (ISF 10+2) be transmitted to CBP for ocean shipments?

No later than 24 hours after the bill of lading is issued
At least 24 hours before vessel departure from the foreign port (Correct answer)
At least 24 hours before the vessel's arrival at a US port
Upon arrival of the cargo at the first US port of entry

Correct answer: At least 24 hours before vessel departure from the foreign port

The ISF 10+2 must be filed no later than 24 hours before the cargo is laden aboard the vessel at the foreign port of departure.

Question 83: When a clinical site receives a shipment of investigational product, what should be done first?

Immediately dispense to the next eligible subject
Enter the receipt in the CRF
Notify the IRB of the new supply
Inspect the shipment, verify contents against the packing list, and check storage conditions were maintained during transit (Correct answer)

Correct answer: Inspect the shipment, verify contents against the packing list, and check storage conditions were maintained during transit

Upon IP receipt, the site must inspect the shipment for damage, verify quantities against the packing list, and confirm transit temperature logs before accepting the product.

Question 84: Which ICH E6(R2) principle requires that the investigator be qualified by training and experience to conduct the clinical trial?

Principle 12
Principle 2
Principle 4 (Correct answer)
Principle 7

Correct answer: Principle 4

ICH E6(R2) Principle 4 states that each individual involved in conducting a trial should be qualified by education, training, and experience.

Question 85: What does the 'Risk Score' metric in CATO's user risk reporting represent?

A calculated score reflecting the user's security risk based on their observed behaviors and violations (Correct answer)
A score assigned by the user's manager through the admin console
The user's likelihood of leaving the organization based on HR data
The network bandwidth risk a user poses to site performance

Correct answer: A calculated score reflecting the user's security risk based on their observed behaviors and violations

CATO's Risk Score for users is a calculated metric based on observed behaviors, security violations, and anomalous activities that collectively indicate the user's security risk level.

Question 86: Who is responsible for ensuring investigational product at the site is stored according to protocol-specified conditions?

The sponsor's drug supply team
The CRO project manager
The IRB/IEC
The Principal Investigator / site pharmacist (Correct answer)

Correct answer: The Principal Investigator / site pharmacist

The PI (often delegating to the site pharmacist) is responsible for ensuring IP is stored under the conditions specified in the protocol and IB.

Question 87: When finalizing a clinical trial protocol, which regulatory body in the United States must grant approval before an investigational drug can be used in human subjects?

Centers for Disease Control and Prevention (CDC)
NIH Office of Research Integrity
Department of Health and Human Services (HHS) Secretary
Food and Drug Administration (FDA) via an IND application (Correct answer)

Correct answer: Food and Drug Administration (FDA) via an IND application

In the US, sponsors must submit an Investigational New Drug (IND) application to the FDA and receive authorization (or absence of a clinical hold) before initiating clinical trials with an investigational drug.

Question 88: What is the role of 'Tags' in CATO's event management and reporting system?

Tags assign bandwidth priority to network flows
Tags trigger automatic remediation workflows
Tags categorize and label events or assets to enable filtered searching and reporting (Correct answer)
Tags encrypt sensitive event log data at rest

Correct answer: Tags categorize and label events or assets to enable filtered searching and reporting

Tags in CATO's event management system categorize and label events or network assets, enabling administrators to filter, search, and build reports based on specific criteria.

Question 89: Which of the following is a key component verified during the site initiation visit regarding laboratory facilities?

IRB meeting minutes
Central lab courier schedule
Data entry credentials
Local lab certification and normal reference ranges (Correct answer)

Correct answer: Local lab certification and normal reference ranges

During SIV, the CRA verifies local laboratory certification and confirms that current normal reference ranges are on file.

Question 90: What step follows data lock in a clinical trial?

Statistical analysis (Correct answer)
Protocol review
Site selection
Participant enrollment

Correct answer: Statistical analysis

After data lock, statistical analysis is conducted to interpret the study findings.

Question 91: What action should a site take if the investigational product temperature excursion alarm is triggered during storage?

Transfer it to a different freezer without documentation
Dispose of the product immediately
Document the excursion and notify the sponsor before using the affected product (Correct answer)
Use the product and note it in the CRF

Correct answer: Document the excursion and notify the sponsor before using the affected product

Temperature excursions must be documented and the sponsor notified to assess product integrity before the IP can be used on subjects.

Question 92: In a randomized controlled trial (RCT), what does 'blinding' primarily aim to prevent?

Regulatory non-compliance
Participant dropout
Protocol deviations
Bias in outcome assessment and participant behavior (Correct answer)

Correct answer: Bias in outcome assessment and participant behavior

Blinding prevents knowledge of treatment assignment from influencing participant behavior or outcome assessors' evaluations, thereby reducing bias.

Question 93: What is a 'medication error' in the context of investigational product management?

Any deviation from the IP storage requirements
A missing drug accountability entry
Any unintended exposure of a subject to the wrong IP dose, route, or product (Correct answer)
An IP shipment that arrives late

Correct answer: Any unintended exposure of a subject to the wrong IP dose, route, or product

A medication error is any unintended deviation in the administration of IP—wrong dose, wrong route, wrong subject, or wrong product.

Question 94: The principle of 'equipoise' in clinical research means that:

The sponsor and investigator must have equal financial interests
There is genuine uncertainty in the expert community about the comparative merits of the treatments being tested (Correct answer)
The study must have equal numbers of male and female participants
Participants must be equally distributed across arms

Correct answer: There is genuine uncertainty in the expert community about the comparative merits of the treatments being tested

Equipoise justifies a randomized controlled trial by confirming that there is honest, professional uncertainty about which treatment is superior.

Question 95: When a clinical trial site closes, which action regarding essential documents is required?

Documents must be archived for the required retention period per regulations (Correct answer)
Documents are returned to the sponsor within 30 days
Documents may be destroyed immediately after the last patient visit
Documents are transferred to the IRB for permanent storage

Correct answer: Documents must be archived for the required retention period per regulations

Essential documents must be retained for the regulatory-required period (commonly 15 years post-marketing or 2 years post-IND closure) to support regulatory inspections.

Question 96: What is the purpose of maintaining a subject screening and enrollment log at a clinical site?

To list all study staff training records
To track SAE reporting timelines
To record IP dispensing
To document all subjects screened, reasons for screen failure, and subjects enrolled to support audit and enrollment tracking (Correct answer)

Correct answer: To document all subjects screened, reasons for screen failure, and subjects enrolled to support audit and enrollment tracking

The screening and enrollment log documents all individuals considered for participation, including screen failures with reasons, to support audit trails and recruitment reporting.

Question 97: Why is it important to document subject recruitment source in the screening log?

To evaluate which recruitment strategies are most effective and to provide an audit trail for regulatory review (Correct answer)
To verify that advertising costs were approved
To calculate site payment per enrolled subject
To determine if the subject has health insurance

Correct answer: To evaluate which recruitment strategies are most effective and to provide an audit trail for regulatory review

Tracking recruitment source helps sponsors evaluate the effectiveness of different strategies and provides regulatory auditors with a complete picture of how subjects were identified.

Question 98: Which type of audit examines whether a vendor or CRO is performing delegated trial tasks in compliance with GCP and contractual requirements?

Regulatory inspection
Vendor/CRO audit (Correct answer)
Systems audit
Internal process audit

Correct answer: Vendor/CRO audit

A vendor or CRO audit evaluates whether outsourced functions are being performed per GCP standards and the terms of the contract.

Question 99: When a subject misses a scheduled study visit, what should the site staff do first?

Unblind the subject to determine if continued participation is needed
Remove the subject from the trial immediately
Attempt to contact the subject to reschedule, document the missed visit, and assess any safety concerns (Correct answer)
Notify the IRB of non-compliance

Correct answer: Attempt to contact the subject to reschedule, document the missed visit, and assess any safety concerns

When a visit is missed, staff should promptly attempt contact to reschedule, document the missed visit per protocol, and assess subject safety.

Question 100: What is the function of a Data Safety Monitoring Board (DSMB)?

Review data for safety concerns (Correct answer)
Market the study
Recruit participants
Monitor site budgets

Correct answer: Review data for safety concerns

A DSMB independently reviews clinical trial data to ensure participant safety and trial integrity.

Question 101: Under the North American Free Trade Agreement (NAFTA) / USMCA, what document can an importer use to claim preferential tariff treatment at the time of entry?

A manufacturer's affidavit notarized by a US consulate
A Certificate of Origin signed by the foreign customs authority
A Certification of Origin completed by the exporter, producer, or importer (Correct answer)
A CBP Form 434 submitted by the licensed customs broker only

Correct answer: A Certification of Origin completed by the exporter, producer, or importer

Under USMCA, preferential tariff treatment is claimed using a Certification of Origin, which can be completed by the exporter, producer, or importer — no specific form is mandated.

Question 102: What does 'blinded randomization' require of the IP packaging and labeling?

Labels must include the IND number
Active and placebo must be labeled with the subject's name
Active and placebo must be indistinguishable in appearance and labeled with only a randomization code (Correct answer)
All kits must display the treatment name

Correct answer: Active and placebo must be indistinguishable in appearance and labeled with only a randomization code

Blinded trial packaging requires active and placebo to look identical, with labels bearing only a code so that neither site staff nor subjects can identify the treatment.

Question 103: What is 'competitive enrollment' in the context of multi-site clinical trials?

An enrollment strategy limited to academic medical centers
Sites competing for the highest IP allocation
A model where multiple sites recruit from a shared enrollment pool on a first-to-enroll basis, without pre-assigned quotas per site (Correct answer)
The practice of poaching subjects from competitor trials

Correct answer: A model where multiple sites recruit from a shared enrollment pool on a first-to-enroll basis, without pre-assigned quotas per site

Competitive enrollment allows all active sites to enroll from a shared pool until the overall target is met, rather than assigning fixed enrollment caps per site.

Question 104: What is a 'final study report' (Clinical Study Report, CSR) and who is responsible for its preparation?

A summary prepared by the IRB for public release
A comprehensive document prepared by the sponsor summarizing the trial's design, conduct, results, and conclusions (Correct answer)
A financial audit report submitted to the FDA
A report prepared by the PI summarizing the site's enrollment

Correct answer: A comprehensive document prepared by the sponsor summarizing the trial's design, conduct, results, and conclusions

The CSR is a comprehensive sponsor-prepared document summarizing the complete trial—design, methods, results, and conclusions—required for regulatory submissions.

Question 105: What is the purpose of a protocol synopsis?

To outline the statistical analysis methods only
To replace the full protocol for regulatory submission
To serve as the informed consent document
To provide a concise summary of the key elements of the study protocol (Correct answer)

Correct answer: To provide a concise summary of the key elements of the study protocol

A protocol synopsis is a condensed summary of the most critical protocol elements, often used for IRB/IEC submissions, feasibility assessments, or internal reviews.

Question 106: What is the primary advantage of using CATO's built-in reporting over exporting logs to an external SIEM?

CATO reports support more data formats than SIEM platforms
CATO reports have longer data retention than any SIEM
Built-in reports automatically trigger network policy changes
Built-in reports provide instant access to pre-correlated SASE data without additional infrastructure (Correct answer)

Correct answer: Built-in reports provide instant access to pre-correlated SASE data without additional infrastructure

CATO's built-in reports offer instant, pre-correlated visibility across SASE components without requiring additional SIEM infrastructure, configuration, or data ingestion pipelines.

Question 107: A CRO contracted by a sponsor defaults on its GCP obligations. Ultimate regulatory responsibility for trial quality remains with:

The IRB/IEC
The CRO
The sponsor (Correct answer)
The principal investigator

Correct answer: The sponsor

GCP stipulates that while a sponsor may transfer duties to a CRO, the sponsor retains ultimate regulatory responsibility for the trial.

Question 108: What is the purpose of a 'first sale' valuation methodology in US customs?

To value goods at the price paid by the US importer to the foreign seller
To value goods at the earliest transaction price in a multi-tier supply chain, potentially lowering dutiable value (Correct answer)
To apply a standard government-set value for goods lacking commercial invoices
To use the manufacturer's suggested retail price as the basis for customs value

Correct answer: To value goods at the earliest transaction price in a multi-tier supply chain, potentially lowering dutiable value

First sale valuation allows importers to use the transaction price between the manufacturer and the middleman (rather than the middleman and the US importer) as the customs value, which can reduce duty liability.

Question 109: What is the 'intent-to-treat' (ITT) analysis population in a clinical trial?

All randomized participants analyzed in their assigned treatment group regardless of actual treatment received (Correct answer)
Only participants who received at least one dose of study drug
Only participants who completed the full study per protocol
Participants who met all eligibility criteria without deviation

Correct answer: All randomized participants analyzed in their assigned treatment group regardless of actual treatment received

The intent-to-treat population includes all randomized participants analyzed according to their randomly assigned treatment, preserving the benefits of randomization and reducing selection bias.

Question 110: What is an 'early termination visit' (ETV) in the context of subject retention?

The final scheduled visit for all subjects
A protocol-specified visit conducted when a subject withdraws from the study before completing all scheduled visits (Correct answer)
An unscheduled visit triggered by an SAE
An interim analysis visit

Correct answer: A protocol-specified visit conducted when a subject withdraws from the study before completing all scheduled visits

An early termination visit is conducted when a subject withdraws early, capturing remaining safety and efficacy data per the protocol.

Question 111: What is a 'run-in period' in the context of clinical trial subject recruitment?

The first week of IP administration
The period during which site staff are trained
The time between screening and randomization for all trials
A pre-randomization phase during which subjects' eligibility, compliance, or baseline characteristics are assessed before full enrollment (Correct answer)

Correct answer: A pre-randomization phase during which subjects' eligibility, compliance, or baseline characteristics are assessed before full enrollment

A run-in period is a pre-randomization phase used to assess subject eligibility, compliance, washout prior medications, or establish a stable baseline.

Question 112: What is the 'randomization ratio' in a clinical trial, and why does it matter for recruitment?

The ratio of SAEs to total enrolled subjects
The proportion of female to male subjects
The ratio of enrolled to screened subjects
The allocation ratio of subjects to treatment arms (e.g., 2:1 active to placebo), which affects sample size and enrollment planning (Correct answer)

Correct answer: The allocation ratio of subjects to treatment arms (e.g., 2:1 active to placebo), which affects sample size and enrollment planning

The randomization ratio defines how subjects are allocated to treatment arms and directly impacts the sample size needed in each arm to power the trial.

Question 113: In a clinical trial, what is a 'comparator product'?

A product used only after unblinding
An approved or investigational product used as a reference in a controlled trial for comparison with the investigational product (Correct answer)
A placebo tablet used only in Phase I trials
The backup supply held at the sponsor's warehouse

Correct answer: An approved or investigational product used as a reference in a controlled trial for comparison with the investigational product

A comparator product is an approved or investigational agent used as a control against which the investigational product's effects are compared.

Question 114: What does it mean for an adverse event to be 'unexpected' in the context of SUSAR reporting?

The event happened without warning signs
The event occurred in fewer than 1% of subjects
The event is unrelated to the investigational product
The nature, severity, or frequency of the event is not consistent with what is described in the reference safety document (e.g., Investigator Brochure) (Correct answer)

Correct answer: The nature, severity, or frequency of the event is not consistent with what is described in the reference safety document (e.g., Investigator Brochure)

An unexpected AE is one whose nature, severity, or frequency is not consistent with current labeling or the Investigator Brochure.

Question 115: What is an 'IP inventory log' used for at a clinical site?

To record current stock levels of IP at the site for accountability and re-order purposes (Correct answer)
To track subject visit dates
To document adverse events related to IP
To summarize protocol deviations

Correct answer: To record current stock levels of IP at the site for accountability and re-order purposes

The IP inventory log tracks the current stock of investigational product at the site, enabling the sponsor to manage supply chain and ensure availability.

CCA — Cato Certified Associate

The CCA (Cato Certified Associate) exam validates foundational knowledge of clinical trial operations, GCP compliance, regulatory requirements, investigational product management, and study design for professionals entering clinical research.

115

Questions

120 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds